Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program

References

• National Alliance on Mental Illness. Mental health facts in America. 2016. Available at: http://www.nami.org/NAMI/media/NAMI-Media/Infographics/GeneralMHFacts.pdf [Last accessed 22 October 2016]
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Offord S, Lin J, Wong B, et al. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Community Ment Health J 2013;49:625-9
   PubMed Web of Science ®Google Scholar
• Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12
   PubMed Web of Science ®Google Scholar
• Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res 2013;4:29-39
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007;68(Suppl 14):14-19
   Google Scholar
• Velligan DI, Mueller J, Wang M, et al. Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006;57:219-24
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010;16:306-24
   PubMed Web of Science ®Google Scholar
• Galuppi A, Turola MC, Nanni MG, et al. Schizophrenia and quality of life: how important are symptoms and functioning? Int J Ment Health Syst 2010;4:31
   PubMed Web of Science ®Google Scholar
• Roche J, McCarry Y, Mellors K. Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adher 2014;8:805-11
   PubMed Web of Science ®Google Scholar
• Ziller V, Kyvernitakis I, Knoll D, et al. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment – the COMPAS study. BMC Cancer 2013;13:407
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905
   PubMed Web of Science ®Google Scholar
• Přikryl R, Přikrylová Kučerová H, Vrzalová M, Cešková E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treat 2012;2012:764-769
   Google Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013;13:340
   PubMed Web of Science ®Google Scholar
• Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc., March 2016
   Google Scholar
• Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011;10:12
   PubMed Web of Science ®Google Scholar
• Chue P, Llorca PM, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Applied Res 2005;5:266-74
   Google Scholar
• Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-408
   PubMed Web of Science ®Google Scholar
• Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Risperdal Consta (risperidone) long-acting injection [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc., March 2016
   Google Scholar
• Velligan DI, Medellin E, Draper M, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J 2011;47:654-9
   PubMed Web of Science ®Google Scholar
• Getzen H, Beasley M, D’Mello DA. Barriers to utilizing long-acting injectable antipsychotic medications. Ann Clin Psychiatry 2014;26:33-8
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. March 2001. Available at: http://www.nationalacademies.org/hmd/∼/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf [Last accessed 22 October 2016]
   Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62
   PubMedGoogle Scholar
• Janssen Pharmaceuticals Inc. Janssen Connect. Available at: http://www.janssencns.com/janssenconnect. Last updated 6 July 2016 [Last accessed 22 October 2016]
   Google Scholar
• Valenstein M, Kavanagh J, Lee T, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 2011;37:727-36
   PubMed Web of Science ®Google Scholar
• Benson CJ, Joshi K, Lapane KL, Fastenau J. Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics. Curr Med Res Opin 2015;31:1437-48
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Introduction to program evaluation for public health programs: a self-study guide. October 2011. Available at: https://www.cdc.gov/eval/guide/cdcevalmanual.pdf [Last accessed 22 October 2016]
   Google Scholar
• Austin PC. Double propensity-score adjustment: a solution to design bias or bias due to incomplete matching. Stat Methods Med Res 2014: published online 17 July 2014, doi: 10.1177/0962280214543508
   Web of Science ®Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ 2013;16:917-25
   PubMedGoogle Scholar
• Chapman SC, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry 2013;26:446-52
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-35
   PubMed Web of Science ®Google Scholar
• Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-13
   PubMed Web of Science ®Google Scholar
• Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000;102:203-10
   PubMed Web of Science ®Google Scholar
• Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007;15:245-58
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 2014;311:1978-87
   PubMed Web of Science ®Google Scholar
• World Health Organization Europe. Health promotion evaluation: recommendations to policy-makers. Report of the WHO European Working Group on Health Promotion Evaluation. 1998. Available at: http://apps.who.int/iris/bitstream/10665/108116/1/E60706.pdf [Last accessed 22 October 2016]
   Google Scholar